Crizotinib, approved by the FDA in 2011 for advanced NSCLC with ALK rearrangements, showed notable efficacy in I/II clinical trials with an ORR of about 60%, despite its initial development as a MET inhibitor. Here, ALK is linked to non-small cell lung carcinoma.